Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Oct 28, 2026
Reporting period
Not applicable
Filed with the SEC
Oct 29, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001171843-26-006977
Filed / recorded
Oct 29, 2026, 9:02 PM UTC
Added to OQRO
Oct 29, 2026, 9:05 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Edesa Biotech, Inc.
Issuer CIK
1540159
Ticker
EDSA
Reporting person
Pardeep Nijhawan
Relationship
Director, Officer, 10% owner
Officer title
Chief Executive Officer
Security
Common Shares
Table
Non-derivative (Table I)
Transaction date
Oct 28, 2026
Transaction code
A
Shares / units
27,602
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
933,595
Ownership form
Direct
Amendment
No
Footnotes from the filing
Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. These restricted stock awards ("RSUs") represent awards received in lieu of 90% of Reporting Person's monthly base salary otherwise payable in cash, reflecting the increase in Reporting Person's annual base salary from $357,696 to $657,423, retroactive for the period from July 1, 2026 through October 10, 2026. The number of RSUs was determined by dividing such portion of the base salary by the 5-day volume weighted average price (VWAP) of the Issuer's common shares through October 27, 2026.
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.